Modulation of Gut Microbiota by Rifaximin in PD Patients
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this clinical trial are to test 1. Whether 1-week rifaximin treatment is able
to restore the gut microbiota in a long-term manner in people with Parkinson's disease? 2.
Whether the restoration of gut microbiota in people with Parkinson's disease is associated
with the reduction of systemic inflammation and circulating exosomal α-synuclein?